Inscrição na biblioteca: Guest
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa
Plasma Medicine
SJR: 0.278 SNIP: 0.183 CiteScore™: 0.57

ISSN Imprimir: 1947-5764
ISSN On-line: 1947-5772

Plasma Medicine

DOI: 10.1615/PlasmaMed.2012005167
pages 241-247

Fast Blood Coagulation of Capillary Vessels by Cold Plasma: A Rat Ear Bleeding Model

Danil Dobrynin
C&J Nyheim Plasma Institute, Drexel University, Camden NJ 08103
Kimberly Wasko
Department of Surgery, Drexel University College of Medicine, Philadelphia, PA, USA
Gary Friedman
Department of Electrical and Computer Engineering, College of Engineering, A. J. Drexel Plasma Institute, Drexel University, Philadelphia, Pennsylvania
Alexander A. Fridman
C&J Nyheim Plasma Institute, Drexel University, Camden, New Jersey 08103
Gregory Fridman
C&J Nyheim Plasma Institute, Drexel University, Camden, New Jersey 08103


Cold atmospheric pressure plasmas previously have been shown to be effective in vitro in generating active species, radicals, and charges, which may aid in various processes of interest to medicine, including blood coagulation. Floating electrode dielectric barrier discharge microsecond-pulsed, high-voltage plasma was used in an animal model of hairless Sprague-Dawley rats to treat an incision on the ear. The results confirm cold plasma's ability to coagulate blood in a live animal model. A small incision in the rat ear, cutting the thin epidermis and slicing through the capillaries, creates a small and controllable wound from which bleeding is observed. Without plasma treatment, the animal bleeds for approximately 2 minutes, whereas a 10-second treatment is sufficient to coagulate blood. Cold plasma floating electrode dielectric barrier discharge was shown to effectively coagulate bleeding small vessels, which may prove beneficial in surgical intervention treatments of, for example, vocal cord surgery, eye surgery, or brain surgery, for which other means of coagulation may be prohibitive. Future animal trials will include larger animals and different bleeding sites, with the potential to move on to human trials.